Raubenheimer JE, Archambault D, Myburgh PH, et al
Closer glucose monitoring during the course is the typical recommendation
Initially, GLP-1s were developed to treat type 2 diabetes and were marketed for that purpose under brand names such as Ozempic (semaglutide), Rybelsus (semaglutide), Victoza (liraglutide), and Mounjaro (tirzepatide)
Not all patients respond equally to GLP-1 agonist therapy, and identifying optimal candidates requires considering multiple factors, including baseline weight, comorbidities, and individual tolerance profiles
This pharmacovigilance system collects reports of suspected adverse drug reactions from healthcare professionals and patients, enabling the identification of previously unrecognised safety signals
Most hormonal shifts during GLP-1 therapy are secondary to weight loss and improved insulin sensitivity, which are generally beneficial